FTC Takes Aim At Generics Pay for Delay



A top priority this year at the Federal Trade Commission (FTC) is to stop "pay-for-delay" agreements between branded and generic drug manufacturers, FTC Chairman Jon Leibowitz told the House Judiciary Subcommittee on Courts and Competition Policy Tuesday.


Name:
E-mail:
Website:  
Please enter your comment below:
Please enter the text below:

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2014 a division of BLR All rights reserved.